Citations

Clear

6273 citation(s) found for "To, Andrew".

Tolerating uncertainty to treat functional motor disorder
Finley, John-Christopher Andrew , Traver, Katie J., Geissler, Elizabeth N., Travis, Mary, Rush, Beth , Travis, Mariah K

Mayo Clinic

BMJ Neurology Open | March 16, 2026 | Volume: 8 | Issue: 1 | Pages: e001446

10.1136/bmjno-2025-001446 | PMID 41852588 Get It

Background Difficulty tolerating the uncertainty of ambiguous or unpredictable situations may influence how patients with functional motor disorder (FMD) respond to treatment. However, only one study has examined the role of intolerance of uncertainty (IU) in FMD treatment. Objectives This study sought to expand on prior findings in a larger sample of patients with FMD who completed an intensive motor-retraining programme. Methods A consecutive cohort of 109 patients with FMD completed a 1-week intensive outpatient motor-retraining programme. Patients rated their IU using the Intolerance of Uncertainty Scale-12 and functional motor outcomes using three empirical measures before and after treatment. Univariate and multivariable analyses were conducted to (1) characterise the rate of elevated IU, (2) evaluate potential changes in IU across the programme, (3) examine whether changes in IU predict improvements in motor functioning and (4) determine if IU incrementally predicts functional improvements in patients with clinically elevated IU. Results Findings revealed that clinically elevated IU was common (yielding a base rate of 44%) and that the ‘prospective’ subtype of IU significantly decreased with 1 week of FMD treatment. Change in IU was not significantly associated with improved functional outcomes across the sample. However, change in prospective IU did predict patient-specific functional outcomes among those with clinically elevated IU ( R 2 =11%). Conclusions Findings support prior work suggesting that certain subtypes of IU are common, modifiable and related to treatment outcomes in FMD. The ‘prospective’ subtype of IU may represent an operative factor that can enhance the efficacy of existing FMD rehabilitation programmes.
Influence of Individual Traits on Measurement Differences in Percent Body Fat
Magee, Meghan K., Miller, Angela D. , Fields, Jennifer B, Lockard, B , Stroiney, Debra A., Jones, Margaret T, Jones, Margaret T , Jagim, Andrew R.

Mayo Clinic

International Journal of Sports Medicine | March 12, 2026 | Volume: 47 | Issue: 08 | Pages: 599-604

10.1055/a-2785-7668 | PMID 41819138 Get It

Abstract The purpose of the current study was to identify the influence of individual characteristics on differences in body fat percentage between air displacement plethysmography and dual-energy X-ray absorptiometry (change in body fat percentage) in 360 collegiate student-athletes. Body fat percentage was obtained from air displacement plethysmography and dual-energy X-ray absorptiometry. A 2 (sex)×3 (Brozek body fat percentage, Siri body fat percentage, and dual-energy x-ray absorptiometry body fat percentage) analysis of variance was used to evaluate the difference between the body fat percentages obtained from air displacement plethysmography and dual-energy x-ray absorptiometry in men and women. The agreement between air displacement plethysmography and dual-energy X-ray absorptiometry was evaluated via Bland–Altman plot and linear regression. Multiple linear regression was used to identify the influence of sex, race, height, and body mass on the change in body fat percentages. Dual-energy X-ray absorptiometry yielded greater body fat percentages in both men (4.8±2.8; p < 0.001) and women (2.2±2.9; p < 0.001) compared to air displacement plethysmography measurements. Proportional and systematic biases were observed between air displacement plethysmography and dual-energy X-ray absorptiometry. Race, height, and mass were significant predictors of the body fat percentage difference between air displacement plethysmography and dual-energy X-ray absorptiometry (R 2=0.445, p<0.001, and standard error of the estimate=2.527). The present study suggests that air displacement plethysmography underestimates body fat percentages when compared to dual-energy X-ray absorptiometry and this underestimation may not be the same for every athlete due to their individual characteristics.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
Tidal Volume Correction of Mechanical Ventilation Device for Use in Hyperbaric Therapy Settings
Clark, William J., Melnyczenko, Andrew R, Pelzer, Abby C, LeTourneau, William Michael, Ramsook, Andrew H , Wiggins, Chad C. , LeTourneau, William M.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 69 | Issue: 10_suppl | Pages: 4134353-4134353

10.4187/respcare.20244134353 Get It

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Cholack, George , Mwangi, Raphael , Vodička, Prokop , Habermann, Thomas M., Hinder, Verena , Robinson, Dennis P. , Feldman, Andrew L., Witzig, T.E. , Villasboas, Jose C., Ansell, Stephen M., Wang, Yucai, Thompson, Carrie A. , Slager, Susan L., Maurer, Matthew, Novak, Anne J. , Cerhan, James R., Witzig, Thomas E. , Habermann, Thomas M. , Cholack, George A , Habermann, Thomas , Ansell, Stephen M , Wang, Yucai , Slager, Susan L , Maurer, Matthew , Novak, Anne J , Cerhan, James R , Feldman, Andrew L. , Ansell, Stephen M. , Link, Brian K. , Wang, Yucai , Slager, Susan L. , Cerhan, James R. , Vodicka, Prokop

Mayo Clinic

British Journal of Haematology | March 10, 2026 | Volume: 208 | Issue: 5 | Pages: 1631-1640

10.1111/bjh.70397 | PMID 41806244 Get It

Summary Family history of haematological malignancy (FHHM) reflects inherited susceptibility to non‐Hodgkin lymphoma (NHL), but its prognostic significance remains poorly understood. We used a cohort study of 1994 NHL patients to evaluate associations between FHHM and clinical outcomes across lymphoma subtypes. We estimated associations, adjusted for sex and lymphoma‐specific prognostic index, of self‐reported FHHM in a first‐degree relative with overall survival (OS), event‐free survival (EFS) and lymphoma‐specific survival (LSS) using multivariable Cox regression models and with failure to achieve EFS at 24 months (EFS24) using logistic regression. FHHM prevalence was 12.8%, and the median follow‐up among survivors was 12.0 years. FHHM was not associated with OS. In subtype‐specific analyses, FHHM was associated with inferior LSS (hazard ratio [HR] = 1.98, 95% confidence interval [CI] 1.11–3.53) in follicular lymphoma (FL); this association and the association with EFS24 failure strengthened among those treated with front‐line immunochemotherapy (EFS24 failure odds ratio = 2.57, 95% CI 1.08–5.99; LSS HR = 2.68, 95% CI 1.09–6.58). In mantle cell lymphoma, FHHM was associated with inferior EFS (HR = 1.70, 95% CI 1.02–2.85). Interaction testing did not demonstrate significant heterogeneity of FHHM effects by lymphoma subtype. FHHM may be associated with adverse outcomes in select NHL groups, particularly FL. These findings warrant further investigation of germline and environmental factors potentially contributing to more aggressive FLs.
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Crowell, Cameron , Mankuzhy, Nikhil P. , Bennett, Julie , Bandopadhayay, Pratiti , Sturm, D., Green, Adam L. , Gupta, Tejpal , Chatterjee, Abhishek , Epari, Sridhar , Chinnaswamy, G., Prasad, Maya , Patel, Sonal, MacNeil, Mary , Vanan, Magimairajan , Larouche, Valérie , Renzi, Samuele , Jones, Jacquelyn , Perreault, Sébastien , Mata-Mbemba, Daddy , Sangatsuda, Yuhei , Yoshimoto, Koji , Lin, Emily , Feddersen, Charlotte R., Pavon-Mengual, Miriam, Vizzini, Olivia, Zápotocký, Michal, Popovacki, Aimee, Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L., Satgunaseelan, Laveniya, Williams, Andrew , Yao, Kristin, Ronsley, Rebecca , Cheng, Sylvia, Eisenstat, David, Andre, N., Matheson, K., Chan, Aimee , Lim-Fat, Mary Jane, Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila, Khan, Sara , Salloum, Ralph , Galvin, Robert , Hawkins, Cynthia, Karajannis, Matthias A. , Jones, David T.W., Ligon, K. L., Jabado, Nada, Erker, Craig , Sturm, Dominik , Chinnaswamy, Girish , Patel, Sohil H , Vanan, Magimairajan Issai , Feddersen, Charlotte , Cruz, Ofelia , Pavon-Mengual, Miriam , Vizzini, Olivia , Zápotocký, Michal , Popovacki, Aimee , Klawinski, Darren , Hansford, Jordan R , Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L , Satgunaseelan, Laveniya , Williams, Andrew , Yao, Kristin , Ronsley, Rebecca , Cheng, Sylvia , Ludlow, Louise , Eisenstat, David , Khuong-Quang, Dong-Anh , Tabouret, Emeline , André, Nicolas , Matheson, Kara , Chan, Aimee , Lim-Fat, Mary Jane , Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila , Khan, Sara , Wright-Nadkarni, Mariah , Salloum, Ralph , Galvin, Robert T , Sener, Ugur , Hawkins, Cynthia , Imber, Brandon S , Karajannis, Matthias A , Jones, David T W , Ligon, Keith L , Jabado, Nada , Erker, Craig , Larouche, Valérie , Hansford, Jordan R. , Satgunaseelan, Laveniya , Sener, Uğur , Hawkins, Cynthia

Mayo Clinic

Clinical Cancer Research | March 9, 2026 | Volume: 32 | Issue: 11 | Pages: 2243-2254

10.1158/1078-0432.ccr-25-3764 | PMID 41801141 Get It

Abstract Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with &lt; NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with &lt; NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
Room for improvement? Evaluating the accuracy of referrals for rectal prolapse to three tertiary care medical centres
Alatout, Mayar H , Saleeb, Andrew G. , Hor, Hoe Yan , Young‐Fadok, Tonia M., Mishra, Nitin , Etzioni, David A. , Shawki, S. F., Merchea, A., Brady, Justin T, Mansour, Rania , Young-Fadok, Tonia M, Shawki, Sherief , Brady, Justin T , Alatout, Mayar H., Merchea, Amit , Brady, Justin T.

Mayo Clinic

Colorectal Disease | March 8, 2026 | Volume: 28 | Issue: 3 | Pages: No page available

10.1111/codi.70418 | PMID 41789560 Get It

Abstract Aim Rectal prolapse is a full‐thickness intussusception of the rectum beyond the anal canal. It is often mistaken for other anorectal pathologies, leading to inaccurate referrals to colorectal surgeons and inappropriate management. However, the frequency of misdiagnosis is not well characterized. We aimed to assess the diagnostic accuracy of rectal prolapse referrals to three tertiary medical centres. Methods This is a retrospective study of patients referred for rectal prolapse to colorectal surgeons at the Mayo Clinic in Rochester, Jacksonville, and Phoenix from 2020 to 2024. The primary outcome is the accuracy of rectal prolapse diagnosis. The secondary outcomes are factors that correlate with diagnostic accuracy. Results Rectal prolapse was inaccurately diagnosed in 38.7% (186/480) of patients. Among misdiagnosed patients, the correct diagnosis was haemorrhoids (68.0%, n = 134), pelvic floor dysfunction (24.3%, n = 48) and rectocele (18.7%, n = 37). A diagnosis of rectal cancer was found in 3 patients (1.5%). The most common presenting symptoms were protrusion (66.3%, n = 345) and bleeding (33.6%, n = 175). Among the referring physicians, only 50.5% ( n = 227) performed an anorectal examination. Overall, there was significant variability in diagnostic accuracy across different specialties, with the highest accuracy from colorectal practices (84.0%) and the lowest from urologists (50.0%). Internal medicine physicians had a lower diagnostic accuracy with anorectal examination than without, though it did not reach statistical significance (44.0% vs. 59.5%, p = 0.2). Conclusion Over one‐third of rectal prolapse referrals were incorrectly diagnosed. This study highlights the opportunity for further training of referring providers on anorectal pathologies to improve diagnostic accuracy which could reduce treatment delays and optimize clinical outcomes.
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients
Mellgard, George , Bazarbachi, Abdul-Hamid, Zanwar, Saurabh , Hegenbart, Ute , Bodanapu, Geethika , Bhutani, Divaya , Chen, G., D'Souza, A, Dispenzieri, Angela, Gertz, Morie, Kumar, Shaji, Lentzsch, Suzanne , Milani, Paolo, Muchtar, E., Palladini, Giovanni, Trajanova, Despina, Patwari, Anannya , Sanchorawala, Vaishali, Mohty, Mohamad, Wang, Shikun , Kastritis, Efstathios, Theodorakakou, Foteini, Cowan, Andrew J, Gertz, Morie A. , D’Souza, Anita , D'Souza, Anita , Gertz, Morie A , Palladini, Giovanni , Sanchorawala, Vaishali , Kastritis, Efstathios , Theodorakakou, Foteini , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Bazarbachi, Abdul Hamid , Dispenzieri, Angela , Milani, Paolo , Muchtar, Eli , Mohty, Mohamad , Kastritis, Efstathios , Theodorakakou, Foteini , Schönland, Stefan , Chakraborty, Rajshekhar

Mayo Clinic

American Journal of Hematology | March 8, 2026 | Volume: 101 | Issue: 4 | Pages: 768-783

10.1002/ajh.70257 | PMID 41793153 Get It

ABSTRACT Systemic AL amyloidosis is a clonal plasma cell dyscrasia, where toxic free light chains (FLCs) lead to vital organ damage, with risk of early mortality despite effective therapies. Notably, there is a paucity of data on the incidence and predictors of early mortality in the daratumumab (Dara) era. We conducted a multi‐center retrospective cohort study to develop and validate a risk‐prediction model for early mortality (all‐cause death within 6 months) in patients treated with Dara‐based frontline regimens. We used univariate analysis to identify covariates for a logistic regression model predictive of 6‐month mortality and generated a clinical risk score. Among 339 patients across eight centers, 36 (10.6%) experienced early mortality. Multivariate analysis identified four independent predictors: NT‐proBN P > 5300 pg/mL (odds ratio [OR] 3.83, p = 0.006), A ge > 75 years (OR 2.96, p = 0.073), absence of t(11;14) on C ytogenetics (OR 3.0, p = 0.022), and E COG performance status (OR 1.72 per unit increase, p = 0.044). The resulting PACE score stratified patients into three risk groups with a 6‐month mortality of 1.2% (low‐risk), 11.7% (intermediate‐risk), and 50.0% (high‐risk). The PACE score demonstrated superior discrimination (C‐index 0.78) for early mortality compared to Mayo 2004 (0.69) and Mayo 2012 (0.55) staging systems. External validation confirmed robust discrimination (C‐index 0.73) with corresponding 6‐month mortality rates of 4.2%, 15.25%, and 37.04% across respective risk groups. The PACE score provides a clinically applicable tool for early mortality risk stratification in AL amyloidosis patients receiving Dara‐based therapy, and will enable improved patient counseling, clinical trial design, and identification of ultra‐high‐risk patients requiring intensive monitoring and novel therapies.
The ALT FLOW early feasibility study 3-year results assessing left atrial to coronary sinus shunting in HFpEF
Fioretti, Francesco , Hibbert, B., Labinaz, Marino , Nazer, Babak, Wiley, Mark, Gupta, Bhanu , Sauer, Andrew J, Shah, Hirak , Sorajja, P, Pineda, Andrés M. , Missov, Emil, Aldaia, Lillian , Koulogiannis, Konstantinos , Tedford, R., Gray, William A., Zahr, Firas, Butler, Javed, Hibbert, Benjamin , Hibbert, Benjamin , Sorajja, Paul , Koulogiannis, Kostantinos P , Tedford, Ryan J , Zahr, Firas , Butler, Javed , Eckman, Peter , Simard, Trevor , Nazer, Babak , Wiley, Mark, Sauer, Andrew J , Shah, Hirak, Tedford, Ryan J. , Zahr, Firas , Butler, Javed

Mayo Clinic

ESC Heart Failure | March 6, 2026 | Volume: 13 | Issue: 2 | Pages: No page available

10.1093/eschf/xvag070 | PMID 41814577 Get It

Abstract Introduction Left atrial-to-coronary sinus (LA-to-CS) shunting through the APTURE transcatheter shunt system aims to unload the LA while preserving the interatrial septum. This article aims to examine the 3-year health status, functional capacity, and clinical outcomes of the ALT-FLOW Early Feasibility Study (EFS). Methods Device safety, patency, and echocardiographic parameters, but also symptoms, health status, and exercise capacity were assessed in patients with left ventricular ejection fraction (LVEF) &gt; 40% (n & 95). Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score predicted 3-year all-cause mortality was compared with observed mortality assessed by Kaplan–Meier analysis using adjudicated events. Predicted and observed HF hospitalization (HFH)-free survival rates were also compared. Results At 3 years, the safety profile remained stable with no new safety signals, and all implanted shunts remained patent. 76.3% of patients improved by at least one NYHA class, and mean KCCQ Overall Summary Scores increased by 25 points from baseline (P &lt; .0001). The 6-min walk distance improved by an average of 39 m (P & .002). These benefits were consistent regardless of baseline pulmonary vascular resistance (PVR). Right heart echocardiographic parameters after 3 years were stable, though a reduction in TAPSE was observed, primarily in the high PVR subgroup. The observed 3-year survival was significantly higher than the MAGGIC-predicted survival (84.4% vs 70.2, respectively; P & .009), as well as the HFH-free survival (68.0% vs 24.0%, respectively; P &lt; 0001). Conclusion In patients with HF and LVEF &gt;40%, the APTURE LA-to-CS shunting confirmed an acceptable safety profile with stable right heart parameters and sustained improvements in symptoms, quality of life, and functional capacity at 3 years. Observed survival and HFH were superior to MAGGIC predictions.
Sex-Specific Associations of α-Synuclein Pathology With Tau Accumulation
Fought, Angela J. , Wiste, Heather J. , Przybelski, Scott A. , Reid, Robert I., Schwarz, Christopher G., Vemuri, Prashanthi, Jack, Clifford R., Lowe, Val J., Petersen, Ronald C., Wa, Rocca, Boeve, Bradley F., Kantarci, Kejal, Initiative, Alzheimer’s Disease Neuroimaging, Weiner, Michael W., Aisen, Paul, Beckett, Laurel, Perrin, Richard J., Toga, Arthur W., Saykin, Andrew J., Mak, Elijah , Reid, Robert I. , Schwarz, Christopher G. , Senjem, Matthew L. , Vemuri, Prashanthi , Jack, Clifford R. , Lowe, Val J. , Petersen, Ronald C. , Rocca, Walter A. , Boeve, Bradley F. , Kantarci, Kejal , Initiative, Alzheimer’s Disease Neuroimaging, Weiner, Michael W. , Aisen, Paul, Beckett, Laurel , Perrin, Richard J. , Toga, Arthur W. , Saykin, Andrew J.

Mayo Clinic

JAMA Network Open | March 4, 2026 | Volume: 9 | Issue: 3 | Pages: e260461

10.1001/jamanetworkopen.2026.0461 | PMID 41779394 Get It

Importance Sex differences are increasingly recognized as modifiers of Alzheimer disease and related dementias, with women exhibiting greater tau burden and faster cognitive decline than men. Even though α-synuclein copathology frequently occurs in Alzheimer disease, its contribution to sex differences in disease progression is unclear. Objective To test whether α-synuclein positivity, measured using cerebrospinal fluid seed amplification assay (SAA), is differentially associated with tau accumulation in women vs men across the Alzheimer disease continuum. Design, Setting, and Participants This cohort study used longitudinal tau positron emission tomography from the Alzheimer’s Disease Neuroimaging Initiative collected between 2015 and 2023, with a median (IQR) follow-up of 1.23 (0.00-3.84) years. Participants were stratified by cerebrospinal fluid α-synuclein seed amplification assay status and sex. Participants were cognitively unimpaired or cognitively impaired (mild cognitive impairment or dementia) at baseline. Exposure Cerebrospinal fluid α-synuclein status determined by SAA and dichotomized as SAA negative or SAA positive. Main Outcomes and Measures Tau burden was quantified as standardized uptake value ratio (SUVr) in the medial temporal composite region of interest. Linear mixed-effects models tested SAA by sex by time interactions on longitudinal tau accumulation, adjusting for baseline age, baseline cognitive status, apolipoprotein E ε4 carrier status, and site. Sample size estimates were calculated to detect 25% and 50% treatment effects with 80% power in those with cognitive impairment. Results Among 415 participants (mean [SD] age, 72.3 [7.6] years; 220 women [53%]; 69 SAA positive [17%] and 346 SAA negative [83%]), there was a significant interaction between SAA status, sex, and time on tau accumulation (β, 0.061; 95% CI, 0.030-0.093; P &amp;lt; .001). Women with positive SAA results exhibited the fastest tau accumulation compared with other groups (0.066 SUVr per year; 95% CI, 0.043 to 0.089 SUVr per year; P &amp;lt; .001). Clinical trials targeting tau pathology in cognitively impaired individuals with 18-month follow-up would require 129 SAA-positive women to detect a 25% treatment effect with 80% power, compared with 518 SAA-negative women. Conclusions and Relevance In this cohort study of participants across the Alzheimer disease continuum, α-synuclein copathology was associated with faster tau accumulation in women than men. These findings may inform sex-specific interpretation of α-synuclein biomarkers and trial design.